A phase i clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 5, 2012, Pages 1441-1447

  Feng, Mary ^a   Smith, David E ^b   Normolle, Daniel P ^c   Knol, James A ^a   Pan, Charlie C ^a   Ben Josef, Edgar ^a   Lu, Zheng ^b   Feng, Meihua R ^b   Chen, Jun ^b   Ensminger, William ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Amifostine; Liver radiation; Radioprotector

Indexed keywords

ACTIVE METABOLITES; AMIFOSTINE; NORMAL TISSUE; PEAK CONCENTRATIONS; PHARMACOKINETIC STUDIES; PHASE I; PRODRUGS; RADIATION-INDUCED LIVER DISEASE; RADIOPROTECTOR; REGRESSION MODEL; RESPONSE RATE; STEREOTACTIC BODY RADIATION THERAPY; WR-1065;

DISEASE CONTROL; DISEASES; PHARMACOKINETICS; RADIATION DAMAGE; REGRESSION ANALYSIS; TUMORS;

RADIOTHERAPY;

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALPHA FETOPROTEIN; AMIFOSTINE; ANTIHYPERTENSIVE AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 2 RECEPTOR ANTIBODY; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; BILE DUCT CARCINOMA; BLOOD PRESSURE MEASUREMENT; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLON METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; HYPOCALCEMIA; HYPONATREMIA; HYPOTENSION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER METASTASIS; MALE; MELANOMA; MULTIMODALITY CANCER THERAPY; NAUSEA; OUTCOME ASSESSMENT; PERICARDITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INDUCED LIVER DISEASE; RADIATION PROTECTION; RISK ASSESSMENT; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AMIFOSTINE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MAXIMUM TOLERATED DOSE; MERCAPTOETHYLAMINES; MIDDLE AGED; ORGANS AT RISK; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIATION INJURIES; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL;

EID: 84863617065     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.10.020     Document Type: Article

References (20)

1. Z. Symon, M. Levi, and W.D. Ensminger Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model Int J Radiat Oncol Biol Phys 50 2001 473 478
2. E. Ben-Josef, D. Normolle, and W.D. Ensminger Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies J Clin Oncol 23 2005 8739 8747
3. J. Seong, H.C. Park, and K.H. Han Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients Int J Radiat Oncol Biol Phys 55 2003 329 336
4. F. Mornex, N. Girard, and C. Beziat Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies - mature results of the French Phase II RTF-1 trial Int J Radiat Oncol Biol Phys 66 2006 1152 1158
5. B. Emami, J. Lyman, and A. Brown Tolerance of normal tissue to therapeutic irradiation Int J Radiat Oncol Biol Phys 21 1991 109 122
6. G.J. Peters, and W.J. van der Vijgh Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): Preclinical aspects Eur J Cancer 31A Suppl 1 1995 S1 S7
7. D.M. Brizel, T.H. Wasserman, and M. Henke Phase III randomized trial of amifostine as a radioprotector in head and neck cancer J Clin Oncol 18 2000 3339 3345
8. D. Antonadou, N. Coliarakis, and M. Synodinou Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer Int J Radiat Oncol Biol Phys 51 2001 915 922
9. D. Normolle, and T. Lawrence Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method J Clin Oncol 24 2006 4426 4433
10. L.A. Dawson, D. Normolle, and J.M. Balter Analysis of radiation-induced liver disease using the Lyman NTCP model Int J Radiat Oncol Biol Phys 53 2002 810 821
11. L.A. Dawson, C.J. McGinn, and D. Normolle Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies J Clin Oncol 18 2000 2210 2218
12. L.M. Shaw, A.T. Turrisi, and D.J. Glover Human pharmacokinetics of WR-2721 Int J Radiat Oncol Biol Phys 12 1986 1501 1504
13. A.K. Souid, G.L. Newton, and R.L. Dubowy Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography Cancer Chemother Pharmacol 42 1998 400 406
14. F. Bai, M.N. Kirstein, and S.K. Hanna New liquid chromatographic assay with electrochemical detection for the measurement of amifostine and WR1065 J Chromatogr B Analyt Technol Biomed Life Sci 772 2002 257 265
15. G. Fiorentini, P. Giovanis, and M. Leoni Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: Results of a phase I study Hepatogastroenterology 48 2001 313 316
16. V.E. Kouloulias, J.R. Kouvaris, and J.D. Kokakis Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: A retrospective analysis Int J Radiat Oncol Biol Phys 59 2004 1148 1156
17. H.S. Bonner, and L.M. Shaw New dosing regimens for amifostine: A pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion J Clin Pharmacol 42 2002 166 174
18. A.E. Korst, C.M. Eeltink, and J.B. Vermorken Pharmacokinetics of amifostine and its metabolites in patients Eur J Cancer 33 1997 1425 1429
19. E. Bardet, L. Martin, and G. Calais Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: Final results of the GORTEC2000-02 phase III randomized trial J Clin Oncol 29 2011 127 133
20. S.I. Bearman Veno-occlusive disease of the liver Curr Opin Oncol 12 2000 103 109